Vasculitis
Conditions
Keywords
endothelin;, blood pressure;, vasculitis
Brief summary
Patients with vasculitis commonly develop cardiovascular disease. The reasons for this are not clear and is not adequately treated with current drugs. It is thus understand the reasons why patients with vasculitis develop cardiovascular disease in order to develop new drugs to reduced this risk. Endothelin is a chemical produced by blood vessels that contributes to the development of hypertension and cardiovascular disease Higher than normal levels of endothelin are seen in patients with vasculitis but how this contributes to cardiovascular disease in patients with vasculitis is not clear. By using drugs that block the effects of endothelin ('endothelin receptor antagonists') the investigators can hopefully reduce the risk of cardiovascular disease in patients with vasculitis. The purpose of the study is to ascertain if endothelin receptor antagonists improve blood vessel function in patients with vasculitis.
Detailed description
Vasculitis patients and healthy controls matched for age, sex will be enrolled into the study. Patients will attend for 4 study days \>1 week apart, whereas controls will attend for single day. Circulating Mφ and other immune cells will be confirmed using FACS prior each study. Study 1 Both patients and control will attend for visit 1: assessment of vascular function using forearm plethysmography as part of case control study. Vasculitis patients will then attend for visits 2, 3 & 4 as part of randomised three way crossover study (randomised & infusions given in a double-blind method): comparison of the effects of selective ETA receptor antagonism (BQ123; 1000nmol/min for 15min iv), mixed ETA/B antagonism (BQ123/788; 1000 nmol/min & 300 nmol/min for 15 min), and placebo on systemic haemodynamics.
Interventions
DRUGBQ123
Intravenous infusion of BQ123 ( selective ETA antagonist )
DRUGBQ123/788
or BQ123/788 (mixed ETA/B antagonists)
DRUGPlacebo
Intravenous infusion of saline
Sponsors
British Heart Foundation
University of Edinburgh
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 100 Years
Healthy volunteers
Yes
Inclusion criteria
* Male or female * Age 18 years and over * Body mass index ≤35 * Normal serum albumin
Exclusion criteria
* Subject with diabetes or current smoking or chronic kidney disease (eGFR \<60ml/min) * Subject with pre-existing cardiovascular disease * Subject is below the age of legal consent, or is mentally or legally incapacitated * History of multiple and/or severe allergic reactions to drugs (including study drugs) * The subject has donated blood (450 ml) within the last 4 weeks * Past or present drug or alcohol abuse including intravenous drug abuse at any time * Participation in another clinical trial within 1 month * Considered to be at high risk of HIV or hepatitis B * Women of child-bearing potential (only women who are post-menopausal or surgically-sterilised will be included in the study)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Study 1 - forearm blood flow | 20mins | Response to endothelium-dependent vasodilators |
| Study 2 - pulse wave velocity | 4 hours | Response of participants to ET antagonism |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Study 1 - tPA release | 20min | Response of fibrinolytic system to endothelial vasodilators |
| Study 1 - baseline pulse wave velocity | Baseline | Baseline arterial stiffness |
| Study 2 - tPA release | 4 hours | Response of participants to ET antagonism |
Countries
United Kingdom
Outcome results
None listed